Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information VANCOUVER, Canada (euro adhoc) - Opawica Explorations Inc. (TSX.V: OPW / OTC: OPWEF / Frankfurt: OE5A) ("Opawica" / the "Company") announces that it has completed ...
Wokingham, England, August 17, 2010 (ots/PRNewswire) - Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK licence for their statin, Livazo(R) (pitavastatin). This follows the completion of the decentralized regulatory procedure, in which the MHRA delivered a positive outcome for pitavastatin whilst ...
Total Group revenues of EUR 592.9 million down 12.9 percent against previous year comparative (EUR 681.0 million) Sales revenues stable at EUR 529.1 million (previous year: EUR 534.0 million) Profit after tax EUR 6.1 million (previous year: EUR 21.1 million) Orders received up 38.7 percent to EUR ...
Wokingham, England, July 22, 2010 (ots/PRNewswire) - Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory Authority (MHRA) acting as the Reference Member State for 16 EU countries. Pitavastatin is indicated for the reduction ...
Basel, Switzerland, July 21, 2010 (ots/PRNewswire) - New data show that Avastin(R) (bevacizumab) based therapy provides a median overall survival (OS) of 14.6 months with a range of chemotherapies routinely used in clinical practice and in a broad population of patients with advanced non-small cell lung cancer ...
Bristol-Myers Squibb and AstraZeneca
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were ...
Bristol-Myers Squibb and AstraZeneca
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found that the addition of ...
Bristol-Myers Squibb and AstraZeneca
Orlando, Florida, June 26, 2010 (ots/PRNewswire) - Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated ...
Nice, France, June 17, 2010 (ots/PRNewswire) - Medtronic, Inc. today announced European launch of the Protecta(TM) portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds). The implantable defibrillators feature Medtronic-exclusive SmartShock(TM) ...
Chicago, June 8, 2010 (ots/PRNewswire) - New data show that first-line treatment with Tarceva(R)(erlotinib) delivered exceptional survival benefits in patients with advanced lung adenocarcinoma (a form of non small cell lung cancer) with epidermal growth factor receptor (EGFR) activating mutations.[1] The phase II data show that Tarceva plus chemotherapy resulted in ...
Rome, June 8, 2010 (ots/PRNewswire) - UK Premiership footballer Rory Delap, renowned for his devastating throw-in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young men and women and raise awareness of ankylosing spondylitis (AS), a poorly understood condition which can affect the lower back. To view the Multimedia News Release, ...
STRATFORD- UPON-AVON, England, June 7, 2010 (ots/PRNewswire) - Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm disorders. To raise awareness of the importance of pulse checking and to ...
Paris, June 7, 2010 (ots/PRNewswire) - Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent ...
ArQule, Inc. and Daiichi Sankyo Co., Ltd.
Woburn, Massachusetts and Tokyo, June 7, 2010 (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) ...
Prague, Czech Republic, May 27, 2010 (ots/PRNewswire) - JetBrains(R), creators of intelligent, productivity-enhancing development tools, today announced the release of YouTrack 2.0, a more customizable version of its fast and innovative keyboard-centric bug and issue tracking system. (Logo: http://www.newscom.com/cgi-bin/prnh/20070118/JBLOGO ) YouTrack ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Strategic management decisions/CEO nomination Cannes (euro adhoc) - Motion network Holding PLC: Cannes may25, 2010 The board is pleased to announce the appointment of french industry veteran Bruno Chatelin as Chief Executive Officer of MNTV and Board Member. Bruno Chatelin, 56, a recognised veteran in the entertainment industry, voting ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information/assay results Vancouver, Canada (euro adhoc) - Opawica Explorations Inc. (TSX.V: OPW / OTC: OPWEF / Frankfurt: OE5A)("Opawica" / the "Company") announces further ...
Total Group revenues of EUR 261 million down 30.5 percent against previous year comparative quarter (EUR 375.3 million) After-tax loss as expected, totalling EUR 4.4 million (previous year: EUR 11.0 million profit) Orders received up 22.2 percent to EUR 293.2 million (previous year: EUR 239.9 ...
All time high in job count of 3,002 jobs Rise to market leadership in Russia in core well services Net profit up more than three times to EUR 8.4 million First time since the IPO: dividend proposal of EUR 0.30 per share Corporate news transmitted by euro adhoc. The issuer/originator is solely ...
Total Group revenues for 2009 of EUR 1,278.3 million down 16.3 percent against previous year (EUR 1,527.2 million) 2009 after-tax profit of EUR 42.0 million down 60.9 percent against previous year (EUR 107.5 million) Dividend proposal EUR 0.60 per share (previous year: EUR 1.00 per share) ...
Charlotte, April 16, 2010 (ots/PRNewswire) - Bank of America Corporation today reported first-quarter 2010 net income of US$3.2 billion compared with a net loss of US$194 million in the fourth quarter and net income of US$4.2 billion a year earlier. After preferred dividends, the company earned US$0.28 per diluted share in the first quarter, up from a loss of US$0.60 per share in the fourth quarter and earnings of ...
Atrium European Real Estate Limited
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 01.04.2010 1 April 2010 Atrium European Real Estate Limited Announcement of Annual Document Atrium European Real Estate Limited (ATX/Euronext: ATRS), one of the leading real estate companies ...
Subsidiary Metric Parking accomplishes turnaround in 2009 Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Financial Figures/Balance Sheet Subtitle: Subsidiary Metric Parking accomplishes turnaround in 2009 Hanover / Germany, 31 March 2010 (euro adhoc) - ... - Operating result of EUR 3.1 million for 2009 exceeds expectations - Positive ...
Paris, March 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for ...
Basel, Switzerland, March 19, 2010 (ots/PRNewswire) - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Financial Figures/Balance Sheet/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, U.S.A., March 12, 2010 (euro adhoc) - Key Figures and Financial Highlights: * Full year revenue increased to EUR 4.3 million * ...
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Annual results 2009 of Bank Sarasin 02.03.2010 Assets under management climb to new peak of CHF 93.7 billion (+34%) - Net new money growth CHF ...
Galway, Ireland, February 17, 2010 (ots/PRNewswire) - Cappella (http://www.cappella-med.com/), Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced the addition of Mr. Eamonn Hobbs to the Board of Directors ( http://www.cappella-med.eu/index.php?option= com_content&view=article&id=181:board-of-directors&catid=4) . According to Mr. Wolfgang ...
Charlotte, North Carolina (ots/PRNewswire) - Bank of America Corporation today reported full-year 2009 net income of US$6.3 billion, compared with net income of US$4.0 billion in 2008. Including preferred stock dividends and the negative impact from the repayment of the U.S. government's US$45 billion preferred stock investment in the company under the Troubled Asset Relief Program (TARP), income applicable to common ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...